Cost-effective use of BISphosphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule - The BISMARK Trial.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- Acronyms BISMARK
- 10 Jun 2017 Biomarkers information updated
- 27 Feb 2016 Status changed from completed to discontinued as per ISRCTN: Current Controlled Trials record.
- 30 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.